In clinical studies, circulating Fas and FasL have been reported to be elevated in patients with biopsy-proven NASH compared to those with hepatic steatosis or controls, including pediatric populations [42–44]. This evidence concerns the gene FASLG and metabolic dysfunction-associated steatohepatitis.